On ECHEMI
Home > Drugs > Doxycycline Hydrochloride Tablets

Doxycycline Hydrochloride Tablets

Function and Efficacy

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent with bactericidal effects at high concentrations. Rickettsia, Mycoplasma, Chlamydia, atypical mycobacteria, and spirochetes are also sensitive to this product. This product is more effective against Gram-positive bacteria than Gram-negative bacteria, but Enterococcus is resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, and Yersinia are sensitive to this product. This product has certain antibacterial activity against Neisseria gonorrhoeae, but penicillin-resistant Neisseria gonorrhoeae is also resistant to doxycycline. Due to the widespread use of tetracyclines over the years, common clinical pathogens have become seriously resistant to this product, including Gram-positive bacteria such as Staphylococcus and most Gram-negative bacilli. This product is different from different varieties of tetracycline antibiotics.

Ingredients

The main ingredient of this product is doxycycline hydrochloride, whose chemical name is 6-methyl-4-(dimethylamino)-3,5,10,12,12a,-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide hydrochloride hemiethanol hemihydrate.

Name Description Content CAS NO. Manufacturer
Doxycycline hydrochlorideIngredients

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent with bactericidal effects at high concentrations. Rickettsia, Mycoplasma, Chlamydia, atypical mycobacteria, and spirochetes are also sensitive to this product. This product is more effective against Gram-positive bacteria than Gram-negative bacteria, but Enterococcus is resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, and Yersinia are sensitive to this product. This product has certain antibacterial activity against Neisseria gonorrhoeae, but penicillin-resistant Neisseria gonorrhoeae is also resistant to doxycycline. Due to the widespread use of tetracyclines over the years, common clinical pathogens have become seriously resistant to this product, including Gram-positive bacteria such as Staphylococcus and most Gram-negative bacilli.

More
10592-13-9 13

Appearance

This product is light yellow tablet.

Indication

1 This product can be used as one of the drugs for the following diseases: (1) Rickettsial diseases, such as epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever; (2) Mycoplasma infection; (3) Chlamydia infection, including psittacosis, venereal disease, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma; (4) relapsing fever; (5) brucellosis; (6) cholera; (7) tularemia; (8) plague; (9) chancroid. It should be used in combination with aminoglycosides to treat brucellosis and plague. 2 Since the common pathogens are currently sensitive to tetracycline

Usage and Dosage

Antibacterial and antiparasitic infections: Adults, 100 mg on the first day, once every 12 hours, followed by 100-200 mg once a day, or 50-100 mg once every 12 hours. Gonorrheal Neisseria urethritis and cervicitis: 100 mg once every 12 hours for 7 days. Non-gonococcal Neisseria urethritis caused by Chlamydia trachomatis, and simple urethritis, cervicitis or rectal infection caused by Chlamydia trachomatis: 100 mg once, twice a day, for at least 7 days. Syphilis: 150 mg once every 12 hours, for at least 10 days. Children over 8 years old: 2.2 mg/kg of body weight once every 12 hours on the first day, followed by 2.2-4.4 mg/kg of body weight once a day, or 50-100 mg once every 12 hours.

Adverse Reactions

1. Digestive system: Oral administration of this product may cause gastrointestinal reactions such as nausea, vomiting, abdominal pain, and diarrhea. There have been occasional reports of esophagitis and esophageal ulcers, which mostly occur in patients who are bedridden immediately after taking the drug. 2. Hepatotoxicity: It is more likely to occur in patients with fatty liver degeneration and pregnant women, and it may also occur in patients without the above conditions. Pancreatitis may occasionally occur, and the pancreatitis caused by this product may also occur simultaneously with hepatotoxicity, and the patient does not have primary liver disease. 3. Allergic reactions: Mostly maculopapular rash and erythema, a small number of patients may have urticaria, angioedema, allergic purpura, pericarditis, and worsening of skin lesions of systemic lupus erythematosus, and exfoliative dermatitis is not common. Occasionally, anaphylactic shock and asthma occur. Some patients who use this product

Precautions

Patients with a history of allergy to tetracyclines are contraindicated.

Special Population Medication

Precautions for children: Children under 8 years old are prohibited to use. Precautions for pregnancy and lactation: 1. This product can enter the fetus through the placental barrier and deposit in the calcium area of teeth and bones, causing fetal tooth discoloration, poor enamel regeneration and inhibiting fetal bone growth. This type of drug has teratogenic effects in animal experiments, so pregnant women should not use it. 2. This product can be secreted from breast milk, and the concentration in breast milk is relatively high. Lactating women should stop breastfeeding when using it. Precautions for the elderly: Not yet clear.

Drug Interactions

1. This product can inhibit the activity of plasma prothrombin, so patients receiving anticoagulant therapy need to adjust the dose of anticoagulants. 2. When barbiturates, phenytoin or carbamazepine are used with this product, the above drugs can induce the activity of microsomal enzymes and cause a decrease in the blood concentration of doxycycline, so the dose of doxycycline must be adjusted.

Storage

Keep away from light and store in sealed container.

Packaging Specification

0.1g (calculated as C22H24N2O8)

Validity Period

36 months

Manufacturer

Jiangsu Pingguang Pharmaceutical (Jiaozuo) Co., Ltd.

  • Founded in:

    2002-03-19
  • Address:

    300 meters north of the extension section of Jiefang Avenue, east of Huazhang Road, Fengxian Economic Development Zone
  • Tax NO.:

    91320321730727420F
  • Registered Funds:

    14.4522 million yuan
  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.